A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 05 Feb 2019 Results published in the Clinical Cancer Research Journal.
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.